Bacterial resistance to antibiotics is rising at an alarming rate, and with only two new classes of antibiotics being developed since 1960's, time is of the essence.
Novobiotic Pharmaceuticals stepped up to the challenge by identifying new natural compounds produced by previously “unculturable” bacteria found in marine and soil environments. Novobiotic Pharmaceuticals then contracted Eurofins Discovery and their DiscoveryOne™ integrated drug discovery team for assistance.
Download this case study to discover:
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK
Email: privacy@technologynetworks.com
© 2019 Technology Networks. All rights reserved
Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy